CAMBRIDGE, Mass., May 17 /PRNewswire/ -- Genstruct Inc., a knowledge- driven discovery company using systems biology to increase the effectiveness of drug discovery and development, today announced the appointment of Michelle Gordon-Savenor to the position of director of Alliance Management. In this position, Ms. Gordon-Savenor will manage the alliances between Genstruct and its large pharmaceutical partners, including such companies as Schering AG and Pfizer.
“Genstruct continues to grow through the development of drug development alliances with large pharmaceutical partners. As these partnerships grow and develop, we need to focus not only on the science, but also on the relationships,” said Keith O. Elliston, PhD, president and CEO of Genstruct. “Michelle comes to us with an unparalleled experience in alliance management through her work at Millennium Pharmaceuticals. Her drive, talent and expertise will help Genstruct foster the strong win-win relationships that advance the pipelines of our partners, and that will continue to make Genstruct the leader in systems biology.”
Prior to joining Genstruct, Ms. Gordon-Savenor was an alliance manager for Millennium Pharmaceuticals, Inc. where she managed the alliances with Monsanto and Aventis. At Millennium, she also held positions as a technical specialist and research associate. Ms. Gordon-Savenor spent two years at the Whitehead Institute for Biological Research as a visiting scholar for the Affymetrix, BMS and Millennium Consortium. She began her career as a research technician at Beth Israel Hospital and then as a research assistant at New England Medical Center.
Ms. Gordon-Savenor has been a speaker at industry events and has had papers published in Molecular Pharmacology, Proceedings of the National Academy of Science and the Journal of Immunology. She earned her A.B. degree in biology and English from Vassar College in Poughkeepsie, N.Y., and was a visiting scholar at the MIT Sloan School of Management in Cambridge, Mass.
About Genstruct
Founded in 2002, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders and inflammation. Genstruct has developed proprietary technologies for the discovery of biomarkers, disease pathways and compound mechanisms of action (MOA). Genstruct engages in internal discovery and external development partnerships, which apply systems biology to accelerate and increase the output of drug discovery and development programs. The privately held company is based in Cambridge, Mass., and its investors include Flagship Ventures and A. M. Pappas & Associates. For more information, please visit http://www.genstruct.com.
Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.
Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com
Genstruct, Inc.
CONTACT: Karen Higgins of A & E Communications for Genstruct,+1-610-831-5723, khiggins@aandecomm.com
Web site: http://www.genstruct.com/
